Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more
Barinthus Biotherapeutics plc (BRNS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.127x
Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has a cash flow conversion efficiency ratio of -0.127x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($84.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Barinthus Biotherapeutics plc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Barinthus Biotherapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kuya Silver Corporation
OTCQB:KUYAF
|
-0.025x |
|
EDAG Engineering Group AG
XETRA:ED4
|
0.052x |
|
OncoCyte Corp
NASDAQ:OCX
|
-0.573x |
|
Atlan Holdings Bhd
KLSE:7048
|
0.149x |
|
Dr Peng Telecom and Media Group Co Ltd
SHG:600804
|
-0.566x |
|
Grey Wolf Animal Health Corp.
V:WOLF
|
0.042x |
|
HILONG HOLDING LTD HD-10
F:8HL
|
N/A |
|
Samsung Publis
KO:068290
|
0.001x |
Annual Cash Flow Conversion Efficiency for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Barinthus Biotherapeutics plc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $130.13 Million | $-28.94 Million | -0.222x | +18.34% |
| 2023-12-31 | $187.00 Million | $-50.92 Million | -0.272x | -358.95% |
| 2022-12-31 | $243.20 Million | $-14.43 Million | -0.059x | +54.01% |
| 2021-12-31 | $252.56 Million | $-32.58 Million | -0.129x | -103.68% |
| 2020-12-31 | $-3.15 Million | $-11.03 Million | 3.504x | +312.44% |
| 2019-12-31 | $-22.08 Million | $-18.76 Million | 0.850x | -- |